Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Carmine Stengone
AddedFeb 15, 2024
UpdatedMay 31, 2026
Carmine Stengone

Carmine Stengone

Board Member, Afraxis

CrunchbaseLinkedInThe Org

Carmine Stengone's Career

Afraxis
Afraxis

San Diego, CA, US

Board Member· Board
Avelas Biosciences
Avelas Biosciences

Los Angeles, CA, US

Board Member· Board
Pipeline Therapeutics
Pipeline Therapeutics

San Diego, CA, US

CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Carmine Stengone's Career

Afraxis
Afraxis
Public$3M62007San Diego, CA, US
Board Member· Board

Leadership at Afraxis

Court R. TurnerCourt R. TurnerBoard Member
Doug DownsDoug DownsBoard Member

Similar to Afraxis

AptinyxAptinyxEvanston, IL, USPharmaceuticalsest. 2015AptinyxEvanston, IL, US · est. 2015

Aptinyx Inc., a US-based bio-pharmaceutical company, specializes in developing novel treatments for brain and nervous system disorders.

Public · $273.9M12
Neurana PharmaceuticalsNeurana PharmaceuticalsSan Diego, CA, USPharmaceuticalsest. 2013Neurana PharmaceuticalsSan Diego, CA, US · est. 2013

Neurana Pharmaceuticals: A US-based specialty pharma company innovating treatments for CNS diseases.

Series A · $60M5
NeurolixisNeurolixisSan Diego, CA, USPharmaceuticalsest. 2011NeurolixisSan Diego, CA, US · est. 2011

San Diego-based Neurolixis, a biopharmaceutical firm innovating treatments for central nervous system diseases.

Seed · $15k6
Axsome TherapeuticsAxsome TherapeuticsNew York City, NY, USTherapeuticsest. 2012Axsome TherapeuticsNew York City, NY, US · est. 2012

American biopharmaceutical firm, Axsome Therapeutics, develops therapies for pain and neurological disorders globally.

Public · $432M383
Avelas Biosciences
Avelas Biosciences
Public$41.9M362008Los Angeles, CA, US
Board Member· Board

Leadership at Avelas Biosciences

Elena StarikovaElena StarikovaBoard Member
Roger TsienRoger TsienFounder
Jay LichterJay LichterBoard Member
Susan StimsonSusan StimsonBoard Member
Timothy ScottTimothy ScottBoard Member

Similar to Avelas Biosciences

Blaze BioscienceBlaze BioscienceSeattle, WA, USImaging, Tumor Paintest. 2010Blaze BioscienceSeattle, WA, US · est. 2010

Seattle-based Blaze Bioscience develops tumor paint technology for precise, real-time cancer cell visualization.

Series B · $55.4M38
avelisbiotech.comavelisbiotech.comScottsdale, AZ, USTechnologyest. 2007avelisbiotech.comScottsdale, AZ, US · est. 2007

Avelis LLC: Innovating natural enhancement technologies for plants, water, and animals since 2007.

Seed · $250k6
Vergent BioscienceVergent BioscienceMinneapolis, MN, USImaging Agentsest. 2016Vergent BioscienceMinneapolis, MN, US · est. 2016

Vergent Bioscience: Pioneering in tumor-targeted molecular imaging for cancer surgery.

Series B · $34.4M13
Pipeline Therapeutics
Pipeline Therapeutics
Series C$112M372017San Diego, CA, US
CEO· C-Suite · Management

Leadership at Pipeline Therapeutics

Daniel LorrainDaniel LorrainCo-Founder
Brian StearnsBrian StearnsCo-Founder
Stefan LarsonStefan LarsonBoard Member
Clare OzawaClare OzawaBoard Member
Eef SchimmelpenninkEef SchimmelpenninkBoard Member
Todd BradyTodd BradyBoard Member

Similar to Pipeline Therapeutics

Autobahn TherapeuticsAutobahn TherapeuticsSan Diego, CA, USRegenerative Medicineest. 2017Autobahn TherapeuticsSan Diego, CA, US · est. 2017

Autobahn Therapeutics: A regenerative medicine company revitalizing health for CNS disorder patients.

Series C · $108.7M25
Novoron BioscienceNovoron BioscienceSan Diego, CA, USPharmaceutical Therapiesest. 2014Novoron BioscienceSan Diego, CA, US · est. 2014

Biotech firm specializing in pharmaceutical therapies for central nervous system regeneration.

Seed · $13.8M5
Halia TherapeuticsHalia TherapeuticsSalt Lake City, UT, USTherapeuticsest. 2017Halia TherapeuticsSalt Lake City, UT, US · est. 2017

Halia Therapeutics: Preclinical biopharma firm innovating therapies for inflammatory and neurological disorders.

Series C · $47.2M11

Carmine Stengone's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to Carmine Stengone

Natalia Oberti NogueraNatalia Oberti NogueraCEO · Pipeline AngelsKatica RoyKatica RoyCo-Founder · Pipeline EquityStephen EllisStephen EllisCo-Founder & CEO · PipelineBruce KellerBruce KellerCEO · PipelineRxFrank CasaleFrank CasaleCo-Founder · Choiceworx